Literature DB >> 2669364

Pharmacokinetics of the antidepressant rolipram in healthy volunteers.

W Krause1, G Kühne, H Matthes.   

Abstract

1. The pharmacokinetics of rolipram were studied in healthy male volunteers using 3H-rolipram and a radioimmunoassay for measurement of unchanged drug. 2. Rolipram was rapidly and completely absorbed after an oral dose of 1 mg. Bioavailability was 73%. 3. Plasma levels of the unchanged drug declined with a terminal half-life of 2 h. The total clearance of rolipram was 2 ml/min per kg. 4. Labelled rolipram was excreted rapidly and completely. The main route of elimination was via the urine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2669364     DOI: 10.3109/00498258909042306

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

Review 1.  Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future.

Authors:  A J Loonen
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

2.  Investigations on the percutaneous absorption of the antidepressant rolipram in vitro and in vivo.

Authors:  J Hadgraft; S Hill; M Hümpel; L R Johnston; L R Lever; R Marks; T M Murphy; C Rapier
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

3.  Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV.

Authors:  Y Tsuboi; S J Shankland; J P Grande; H J Walker; R J Johnson; T P Dousa
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses.

Authors:  David R Sprague; Masahiro Fujita; Yong Hoon Ryu; Jeih-San Liow; Victor W Pike; Robert B Innis
Journal:  Nucl Med Biol       Date:  2008-05       Impact factor: 2.408

5.  Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers.

Authors:  W Krause; G Kühne; N Sauerbrey
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Inderjit Singh; Avtar K Singh
Journal:  Exp Neurol       Date:  2008-08-07       Impact factor: 5.330

Review 7.  Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Authors:  Andrei G Malykh; M Reza Sadaie
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.